Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Marsili

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Vaccine|January 1, 1993
Preparation and immunogenicity of an inactivated hepatitis A vaccineV Pellegrini, N Fineschi, G Matteucci, et al.
International Journal of Immunopathology and Pharmacology|December 21, 2013
Anaesthesia management in patients with multiple chemical sensitivity syndromeA Piroli, A Ciccozzi, E Petrucci, et al.
Infection and Immunity|January 1, 1994
Depression of liver metabolism and induction of cytokine release by diphtheria and tetanus toxoids and pertussis vaccines: role of Bordetella pertussis cells in toxicityG Fantuzzi, M Sironi, R Delgado, et al.
Vaccine|October 1, 1991
Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDaA Podda, L Nencioni, I Marsili, et al.
Infection and Immunity|May 1, 1990
Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping coughL Nencioni, M Pizza, M Bugnoli, et al.
The Journal of Pediatrics|July 1, 1993
Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and childrenA Podda, E Carapella De Luca, L Titone, et al.
The Journal of Pediatrics|May 1, 1992
Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old childrenA Podda, E C De Luca, L Titone, et al.
Developments in Biologicals|February 24, 2001
Physicochemical characterisation of the pertussis vaccineC Ceccarini, M Contorni, P Costantino, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Vaccine|January 1, 1993
Preparation and immunogenicity of an inactivated hepatitis A vaccineV Pellegrini, N Fineschi, G Matteucci, et al.
International Journal of Immunopathology and Pharmacology|December 21, 2013
Anaesthesia management in patients with multiple chemical sensitivity syndromeA Piroli, A Ciccozzi, E Petrucci, et al.
Infection and Immunity|January 1, 1994
Depression of liver metabolism and induction of cytokine release by diphtheria and tetanus toxoids and pertussis vaccines: role of Bordetella pertussis cells in toxicityG Fantuzzi, M Sironi, R Delgado, et al.
Vaccine|October 1, 1991
Phase I clinical trial of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin combined with FHA and 69 kDaA Podda, L Nencioni, I Marsili, et al.
Infection and Immunity|May 1, 1990
Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping coughL Nencioni, M Pizza, M Bugnoli, et al.
The Journal of Pediatrics|July 1, 1993
Immunogenicity of an acellular pertussis vaccine composed of genetically inactivated pertussis toxin combined with filamentous hemagglutinin and pertactin in infants and childrenA Podda, E Carapella De Luca, L Titone, et al.
The Journal of Pediatrics|May 1, 1992
Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: safety and immunogenicity in 12- to 24- and 2- to 4-month-old childrenA Podda, E C De Luca, L Titone, et al.
Developments in Biologicals|February 24, 2001
Physicochemical characterisation of the pertussis vaccineC Ceccarini, M Contorni, P Costantino, et al.
Pageof 2